new_0222_0430|OMIC|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|sga_expense|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|short_interest|forward_pe_ratio|forward_pe_ratio_1y|forward_ps_ratio|forward_ps_ratio_1y|quarterly_eps_estimates|quarterly_sales_estimates|quarterly_eps_surprise|quarterly_sales_surprise|quarterly_eps_actual|quarterly_sales_actual|sales_est_0y|sales_est_1y|price_target|consensus_recommendation|price_target_num_est|eps_est_0y|eps_est_1y|r_and_d_expense|reconciled_depreciation|interest_expense_non_operating|land_and_improvements|buildings_and_improvements|other_properties|machinery_furniture_equipment|price_next_month|price_second_month
new_0222_0430|OMIC|1|Singular Genomics Systems Inc Total Current Assets (Quarterly) (USD)|Singular Genomics Systems Inc Cash and Short Term Investments (Quarterly) (USD)|Singular Genomics Systems Inc Inventories (Quarterly) (USD)|Singular Genomics Systems Inc Net PP&E (Quarterly) (USD)|Singular Genomics Systems Inc Goodwill and Intangibles (Quarterly) (USD)|Singular Genomics Systems Inc Total Liabilities (Quarterly) (USD)|Singular Genomics Systems Inc Total Current Liabilities (Quarterly) (USD)|Singular Genomics Systems Inc Total Long Term Liabilities (Quarterly) (USD)|Singular Genomics Systems Inc Total Deposits (Quarterly) (USD)|Singular Genomics Systems Inc Book Value (Quarterly) (USD)|Singular Genomics Systems Inc Retained Earnings (Quarterly) (USD)|Singular Genomics Systems Inc Treasury Stock (Quarterly) (USD)|Singular Genomics Systems Inc EV to Revenues|Singular Genomics Systems Inc EV to Earnings|Singular Genomics Systems Inc EV to Free Cash Flow|Singular Genomics Systems Inc EV to Assets (Quarterly)|Singular Genomics Systems Inc PS Ratio|Singular Genomics Systems Inc PE Ratio|Singular Genomics Systems Inc Price to Book Value|Singular Genomics Systems Inc PEG Ratio|Singular Genomics Systems Inc Debt to Equity Ratio|Singular Genomics Systems Inc Dividend Yield|Singular Genomics Systems Inc Shareholder Yield (TTM)|Singular Genomics Systems Inc Percent of Shares Outstanding Short|Singular Genomics Systems Inc Total Receivables (Quarterly) (USD)|Singular Genomics Systems Inc Total Payables (Quarterly) (USD)|Singular Genomics Systems Inc Total Capital Stock (Quarterly) (USD)|Singular Genomics Systems Inc Return on Invested Capital|Singular Genomics Systems Inc Quality Ratio Score|Singular Genomics Systems Inc Momentum Score|Singular Genomics Systems Inc Beta (1Y)|Singular Genomics Systems Inc Sustainable Growth Rate (TTM)|Singular Genomics Systems Inc Institutional Investor Ownership Percentage|Singular Genomics Systems Inc Average Diluted Shares Outstanding (Quarterly)|Singular Genomics Systems Inc Total Employees (Annual)|Singular Genomics Systems Inc EPS Diluted (Quarterly) (USD)|Singular Genomics Systems Inc SG&A Expense (Quarterly) (USD)|Singular Genomics Systems Inc Shares Outstanding|Singular Genomics Systems Inc Repurchase of Capital Stock (Quarterly) (USD)|Singular Genomics Systems Inc Ordinary Shares Number (Quarterly)|Singular Genomics Systems Inc Payout Ratio|Singular Genomics Systems Inc Quick Ratio (Quarterly)|Singular Genomics Systems Inc Normalized Diluted EPS (Quarterly) (USD)|Singular Genomics Systems Inc Stock Buybacks (Quarterly) (USD)|Singular Genomics Systems Inc Effective Tax Rate (TTM)|Singular Genomics Systems Inc Return on Equity|Singular Genomics Systems Inc Net Income (TTM) (USD)|Singular Genomics Systems Inc Revenue (TTM) (USD)|Singular Genomics Systems Inc Dividend Per Share (Quarterly) (USD)|Singular Genomics Systems Inc Revenue (Quarterly) (USD)|Singular Genomics Systems Inc Gross Profit (Quarterly) (USD)|Singular Genomics Systems Inc Pre-Tax Income (Quarterly) (USD)|Singular Genomics Systems Inc Net Income (Quarterly) (USD)|Singular Genomics Systems Inc Net Interest Income (Quarterly) (USD)|Singular Genomics Systems Inc Price (USD)|Singular Genomics Systems Inc Total Return Price (USD)|Singular Genomics Systems Inc Enterprise Value (USD)|Singular Genomics Systems Inc 30-Day Average Daily Volume|Singular Genomics Systems Inc 1 Year Price Returns (Daily)|Singular Genomics Systems Inc Short Interest|Singular Genomics Systems Inc PE Ratio (Forward)|Singular Genomics Systems Inc PE Ratio (Forward 1y)|Singular Genomics Systems Inc PS Ratio (Forward)|Singular Genomics Systems Inc PS Ratio (Forward 1y)|Singular Genomics Systems Inc Quarterly EPS Estimates (USD)|Singular Genomics Systems Inc Quarterly Revenue Estimates (USD)|Singular Genomics Systems Inc Quarterly EPS Surprise|Singular Genomics Systems Inc Quarterly Revenue Surprise|Singular Genomics Systems Inc Quarterly Actual EPS (USD)|Singular Genomics Systems Inc Quarterly Actual Revenue (USD)|Singular Genomics Systems Inc Revenue Estimates for Current Fiscal Year (USD)|Singular Genomics Systems Inc Revenue Estimates for Next Fiscal Year (USD)|Singular Genomics Systems Inc Price Target (USD)|Singular Genomics Systems Inc Consensus Recommendation|Singular Genomics Systems Inc Price Target Num Estimates|Singular Genomics Systems Inc EPS Estimates for Current Fiscal Year (USD)|Singular Genomics Systems Inc EPS Estimates for Next Fiscal Year (USD)|Singular Genomics Systems Inc Research and Development Expense (Quarterly) (USD)|Singular Genomics Systems Inc Reconciled Depreciation (Quarterly) (USD)|Singular Genomics Systems Inc Non-Operating Interest Expense (Quarterly) (USD)|Singular Genomics Systems Inc Land and Improvements (Quarterly) (USD)|Singular Genomics Systems Inc Buildings and Improvements (Quarterly) (USD)|Singular Genomics Systems Inc Other Properties (Quarterly) (USD)|Singular Genomics Systems Inc Machine, Furniture & Equipment (Quarterly) (USD)||
new_0222_0430|OMIC|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_per_share_metric|percent_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_USD_metric|figure_whole_USD_price|figure_money_USD_per_share_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric||
new_0222_0430|OMIC|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|quarterly|monthly|quarterly|quarterly|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|monthly|monthly|monthly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0430|OMIC|5|91|91||91||91|91|91||91|91||||1.44324324324||||1.43827160494|||1.44324324324||15.5||91|91||||||30.625|91.3333333333|91.5|91.3333333333|91.3333333333|26.6666666667|91.25|91|||91.3333333333|91.3333333333|||91|||||91.3333333333|91.3333333333|91.3333333333|1.44324324324|1.44324324324|1.44324324324|1.4358974359||15.5|||1.44117647059|1.44117647059|91.5|91.5|92||92|92|16.6153846154|13.5|18|9|18|14.4|14.4|91.3333333333|91.3333333333|91.3333333333|||91|91||
new_0222_0430|OMIC|6|3|3||3||3|3|3||3|3||||185||||162|||185||16||3|3||||||8|6|2|6|6|6|4|3|||6|6|||3|||||6|6|6|185|185|185|156||16|||34|34|6|6|1||1|1|13|16|12|24|12|15|15|6|6|6|||3|3||
new_0222_0430|OMIC|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0430|OMIC|202003||||||||||||||||||||||||||||||||||69.3823||-0.0757|1.377||||||-0.0757|-0.01||||||||-5.253|-5.253|0.15||||||||||||||||||||||||4.026|0.131|0.066||||||
new_0222_0430|OMIC|202006||||||||||||||||||||||||||||||||||69.3823||-0.0987|1.443||||||-0.0987|0.01||||||||-6.847|-6.847|-0.079||||||||||||||||||||||||5.325|0.139|0.235||||||
new_0222_0430|OMIC|202009||||||||||||||||||||||||||||||||||69.3823||-0.1143|1.698||-0.03||||-0.1136|||||||||-7.933|-7.933|-0.126||||||||||||||||||||||||6.08|0.171|0.202||||||
new_0222_0430|OMIC|202012|27.571|26.919||2.368||82.057|3.69|78.367||-51.555|-53.125|||||||||||||||0.427|0.001|||||||69.3823||-0.114|1.769|||68.041|||-0.1119|-0.047|||-27.945|||||-7.912|-7.912|-0.154||||||||||||||||||||||||5.816|0.198|0.215|||2.642|0.931||
new_0222_0430|OMIC|202103|151.506|150.121||2.75||228.965|7.906|221.059||-73.342|-77.046||||-60.5189|||||||||||0.657|0.001||||||2.1385|69.3823|138|-0.345|3.654|69.3823||68.041|||-0.3133|-2.984|||-46.613|||||-23.921|-23.921|-0.057|27|27|1874.5741|||||||||||||||||||||6.608|0.211|0.188|||2.948|1.218||
new_0222_0430|OMIC|202106|378.869|371.668||3.434||17.402|8.152|9.25||366.578|-114.525||||-39.0024||||5.3619|||||0.4362||2.698|0.007||||||69.8753|31.6289|169|-1.18|6.201|71.5263||71.5263|||-1.1807|-235.66|||-77.245|||||-37.479|-37.479|0.181|27.48|27.48|1603.4297|143930.2333||312010|||||-0.2146||-101.8404||-0.4332|||12.3707|31.5|1.8|4|-0.8605|-1.2185|7.682|0.255|0.232|||3.48|1.625|18.05|16.53
new_0222_0430|OMIC|202109|364.227|357.013||4.917||18.763|5.991|12.772||352.068|-132.136||||-9.8836||||2.2863|||||1.2089||2.39|0.007||||||54.2392|71.7219|200|-0.25|8.551|71.9342||71.9342|||-0.25|1.445|||-86.923|||||-17.611|-17.611|-0.143|11.19|11.19|457.7987|176657.8||869623|||||-0.2436||-2.6273||-0.25|||12.3507|30.25|1.8|4|-1.1623|-1.3143|8.91|0.303|0.234|||3.854|1.66|13.85|11.42
new_0222_0430|OMIC|202112|||||||||||||||-10.4892||||2.366|||||1.597|||||||||56.574||||||||||||||||||||||11.56|11.56|485.8513|373322.2||1150799|||60.9066|14.6147|-0.3152||||||13.6766|13.6766|28.25|1.8|4|-1.6938|-1.3762||||||||7.75|7.17
new_0222_0430|OMIC|202203|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.31|||||||||||||||||||||
new_0222_0430|OMIC|202206|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.32|1.7907||||||||||||||||||||
new_0222_0430|OMIC|202209|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.345|3.1719||||||||||||||||||||
new_0222_0430|OMIC|202212|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.355|8.1758||||||||||||||||||||